Arcturus Therapeutics (NASDAQ:ARCT) Downgraded to Sell at ValuEngine

Share on StockTwits

ValuEngine lowered shares of Arcturus Therapeutics (NASDAQ:ARCT) from a hold rating to a sell rating in a report published on Monday, June 17th, ValuEngine reports.

Other research analysts have also recently issued reports about the stock. Zacks Investment Research upgraded shares of Arcturus Therapeutics from a hold rating to a buy rating and set a $8.50 price target on the stock in a report on Tuesday, April 16th. Chardan Capital reaffirmed a buy rating and issued a $18.00 price objective on shares of Arcturus Therapeutics in a research report on Tuesday, March 19th. Laidlaw started coverage on shares of Arcturus Therapeutics in a research report on Tuesday, February 19th. They issued a buy rating on the stock. Roth Capital reaffirmed a buy rating on shares of Arcturus Therapeutics in a research report on Wednesday, February 20th. Finally, HC Wainwright started coverage on shares of Arcturus Therapeutics in a research report on Friday, April 5th. They issued a buy rating and a $15.00 price objective on the stock. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. The stock presently has a consensus rating of Buy and an average target price of $13.83.

Arcturus Therapeutics stock traded down $0.09 during midday trading on Monday, hitting $9.41. 33,900 shares of the stock were exchanged, compared to its average volume of 51,618. Arcturus Therapeutics has a 52-week low of $4.11 and a 52-week high of $10.29. The company has a market capitalization of $123.95 million, a PE ratio of -4.36 and a beta of 2.30. The stock’s 50-day simple moving average is $7.30. The company has a quick ratio of 2.51, a current ratio of 2.51 and a debt-to-equity ratio of 2.43.

Arcturus Therapeutics (NASDAQ:ARCT) last released its quarterly earnings results on Monday, May 13th. The biotechnology company reported ($0.68) earnings per share for the quarter, missing the consensus estimate of ($0.53) by ($0.15). Arcturus Therapeutics had a negative return on equity of 132.46% and a negative net margin of 124.59%. The firm had revenue of $4.35 million for the quarter, compared to analysts’ expectations of $3.47 million. As a group, analysts predict that Arcturus Therapeutics will post -2.32 EPS for the current year.

Several hedge funds and other institutional investors have recently bought and sold shares of ARCT. ARK Investment Management LLC raised its position in shares of Arcturus Therapeutics by 13.7% in the first quarter. ARK Investment Management LLC now owns 927,144 shares of the biotechnology company’s stock valued at $6,332,000 after purchasing an additional 111,968 shares during the period. Nikko Asset Management Americas Inc. bought a new stake in shares of Arcturus Therapeutics in the first quarter valued at approximately $438,000. Finally, Creative Planning bought a new stake in shares of Arcturus Therapeutics in the first quarter valued at approximately $416,000. 11.15% of the stock is currently owned by institutional investors.

About Arcturus Therapeutics

Arcturus Therapeutics Ltd., an RNA medicines company, focuses on treatment of liver and respiratory diseases. The company's pipeline of RNA therapeutics include programs pursuing rare diseases, hepatitis B, non-alcoholic steatohepatitis, cystic fibrosis, and vaccines. The company owns LUNAR lipid-mediated delivery and Unlocked Nucleomonomer Agent (UNA) technology, including UNA Oligomers, which are covered by its patent portfolio, including 152 patents and patent applications issued in the United States, Europe, Japan, China, and internationally.

Further Reading: Stochastic Momentum Index (SMI)

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Arcturus Therapeutics (NASDAQ:ARCT)

Receive News & Ratings for Arcturus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcturus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.